30 Years of Autism = $7 Trillion in Costs
Next Decade Will Add More Trillions to Looming Public Financial Burden: The lifetime cost of autism for U.S. cases identified in the 30 years between 1990 and 2019 is estimated to be $7 trillion. If costs for the next decade 2020-2029 are included, the lifetime cost will reach up to $15 trillion. The findings were reported in a new study in the journal Research in Autism Spectrum Disorders. In “The Lifetime Social Cost of Autism: 1990–2029”, authors Janet Cakir, Richard Frye, and Stephen Walker compiled findings from peer-reviewed published studies on the number of cases of autism for the decades 1990-2019 and the lifetime cost of autism per person in the U.S.
Potential Anti-inflammatory Treatment for Autism
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by impaired social interactions and communication. 1 ASD affects about 1 in 59 children 2 and is estimated to reach 1 in 40 children in 2025. 3 The complexity of the factors involved in the clinical picture of ASD, along with the lack of reliable biomarkers 4 and specific pathogenesis 5 has prevented the development of effective treatments.
Autism Prevalence – Examining the Myths and Truths
SafeMinds interviews the New Jersey investigator for the U.S. Centers for Disease Control and Prevention’s (CDC) autism prevalence report of 1 in 59 children, examining the truths and myths behind the latest numbers from the Federal Government. The big news for May was the release of new autism prevalence numbers from the Federal Government. The CDC study by the Centers for Disease Control & Prevention (CDC) found that 1 in 59 children have autism, up from the 1 in 68 they reported just two years ago. This alarming increase compelled SafeMinds to call for an emergency meeting with the U.S. Department of Health and Human Services (HHS). Along with other autism organizations, SafeMinds is demanding a Federal Autism Strategic Plan that address the urgent crisis of autism.
Autism & Mental Health: Problems & Solutions
Two new studies point to higher and growing healthcare costs for autism spectrum disorders (ASD) across the lifespan, particularly in the area of mental health. A new model program in New York might have an answer to this critical problem. A new study reports that children with autism were up to 30 times more likely to use emergency departments (ED) than youth without ASD. Many of those visits were for non-urgent ED visits, which is a costly way to provide routine healthcare. Up to 13 percent of visits were for behavioral or psychiatric problems, far more than for children without autism, for whom less than two percent of visits were for psychiatric problems. Youth with ASD were also likely to have repeat visits to the ED and more likely to be admitted to a psychiatric unit or medical floor. The study was a review of the literature published between 1985 and 2016.
Why We Can and Should Focus on Autism Prevention
In light of the recent increase in autism from 1 in 68 to 1 in 59 children in just two years, a new video by scientist Bruce Lanphear it worth watching and sharing. The video makes the case for preventing chronic diseases like autism rather than chasing down genes or finding cures. In “Cause or Cure. Is the relentless pursuit of a cure hazardous to our health?”, Dr. Lanphear says that more health and science dollars need to be directed to prevention. His approach to prevention is identifying environmental exposures that promote disease and then investing in removing these exposures.
Two Treatments with Positive Results and the High Cost of Autism
Two abstracts being presented this week at the annual conference of the American Academy of Neurology report positive outcomes from two treatments for autism. A third article on healthcare utilization reports double the cost for adults with autism. A MitoCocktail was tested in eleven children with autism and mitocondrial (mt) dysfunction. Mt dysfunction is common in autism. The MitoCocktail contained carnitine, coenzyme Q10 and alpha-lipoic acid. Investigators Craig Newschaffer and colleagues at Drexel University conclude: “This small pilot study supports the hypothesis that in ASD MitoCocktail may have a therapeutic benefit, improving mt function and maladaptive behavior and speech. Larger placebo-controlled trials are needed to demonstrate efficacy.”
